Czym skorupka za młodu... czyli o wewnątrzmacicznym ograniczeniu wzrostu płodu i jego późniejszych konsekwencjach

• Authors: Romuald Zabielski , Michał Mickiewicz

Title variants

EN

What youth is used to... or about intrauterine growth retardation and its later consequences

• Languages of publication: PL EN

Abstracts

EN

Fetal intrauterine growth retardation (IUGR) is currently a serious civilization problem. Eight to nine% of newborns are displaying signs of IUGR every year. IUGR is caused in most instances by misbalanced diet of pregnant mother (in terms of protein and energy). This inhibits system A activity responsible for amino acid transport across the placenta to the fetus. IUGR newborns are characterized by low birth weight, which is compensated soon after birth, but by the expansion of fat tissue. IUGR children are often overweight and less active. It is difficult to reduce overweight in IUGR due to modification of developmental program into a so called "thrifty phenotype". In adults, IUGR manifests its long-lasting health consequences such as hypercholesterolemia, arterial hypertension, coronary heart disease, obesity and diabetes type 2, commonly named as metabolic syndrome (syndrome X). Studies on animals suggest that IUGR diagnosed in perinatal period followed by continuous controlled diet may reduce symptoms of metabolic syndrome.

• Journal: Kosmos
• Year: 2010
• Volume: 59
• Issue: 3-4
• Pages: 327-336

Dates

published

2010

Contributors

author

Romuald Zabielski

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, Nowoursynowska 159, 02-766 Warszawa, Polska

author

Michał Mickiewicz

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, Nowoursynowska 159, 02-766 Warszawa, Polska

References

• Alberti K. G., Zimmet P., Shaw J., 2006. Metabolic syndrome - a new world - wide definition. A Consensus Statement from the International Diabetes Federatio. Diabet. Metabol. 23, 469-480.
• Acog (American College of Obstetricians & Gynecologists), 2000. Clinical management guidelines for obstetrician-gynecologists: Intrauterine growth restriction.. Obstet. Gynecol. 95, 1-10.
• Ada (American Diabetes Association), 2009. Standards of Medical Care In Diabetes. Diabet. Care 32 (Suppl. 1), S13-S61.
• Aha (American Heart Association), 1994. Heart and stroke facts: 1994 statistical supplement. American Heart Association, Dallas.
• Alberti K. G., Zimmet P., Shaw J., 2006. Metabolic syndrome - a new world - wide definition. A Consensus Statement from the International Diabetes Federatio. Diabet. Metabol. 23, 469-480.
• Barker D. J., Hales C. N., Fall C. H., Osmand C., Phipps K., Clark P. M. S., 1993. Type 2 (non-insulindependent) diabetes mellitus hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36, 62-7.
• Blackwood R. A., Leppert P. C., Barker D., 1985. The tendency to Iugr in Preterm Infants Born to Young Women Enrolled in a Comprehensive Prenatal Program. Am. J. Perinatol. 2, 70-73.
• Blössner M., De Onis M., 2005. Malnutrition. Raport Światowej Organizacji Zdrowia WHO, 12, 1-10.
• Bond M. E., Williams M. J., Crammond B., LOFF B., 2010. Taxing junk food: applying the logic of the Henry tax review to food. Med. J. Aust. 193, 472-473.
• Claris O., Beltrand J., Levy-Marchal C., 2010. Consequences of intrauterine growth and early neonatal catch-up growth. Sem. Perinatol. 34, 207-210.
• Dahlquist G. G., Patterson C., Soltesz G., 1999. Perinatal risk factors for childhood type-1 diabetes in Europe. Diabet. Care 22, 1698-1702.
• Dahri S., Snoeck A., Reusens-Billen B., Remacle C., Hoet J .J., 1991. Islet function in offspring of mothers on low-protein diet during gestation. Diabetes 40, 115-120.
• Dcahd (Department of Child and Adolescent Health and Development), 1999. Interventions for physical growth and psychological development. Raport Światowej Organizacji Zdrowia, WHO.
• Eriksson J., Forsen T., Tuomilehto J., 2001. Size at birth childhood growth, and obesity in adult life. Int. J. Obesit. 25, 735-740.
• Esteghamati A., Ashraf H., Khalilzadeh O., Zandieh A., Nakhjavani M., Rashidi A., Haghazali M., Asgari F., 2010. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007). Nutrit. Metabol. 7, 26.
• Gatford K. L., Simmons R. A., De Blasio M. J., Robinson J. S., Owens J. A., 2010. Review: Placental Programming of Postnatal Diabetes and Impaired Insulin Action after IUGR. Trophoblast Res. 24, S60-S65.
• González-Zapata L. I., Alvarez-Dardet C., Millstone E., Clemente-Gómez V., Holdsworth M., Ortiz-Moncada R., Lobstein T., Sarri K, De Marchi B., Horvath K. Z., 2010. The potential role of taxes and subsidies on food in the prevention of obesity in Europe. J. Epidemiol. Commun. Health 64, 696-704.
• Guilloteau P., Zabielski R., Hammon H. M., Metges C. C., 2010. Nutritional programming of gastrointestinal tract development. Is pig a good model for human? Nutrtion Res. Rev. 23, 4-22.
• Hales N. C., Barker D. J. P., 1992. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35, 595-601.
• Hales N. C., Barker D. J. P., 2001. The thrifty phenotype hypothesis. Brit. Med. Bull. 60, 5-20.
• Hales N. C., Barker D. J. P., Clark P. M., Cox L. J., Fall C., Osmond C., Winter P. D., 1991. Fetal and infant growth and impaired glucose tolerance at age 64. Brit. Med. J. 303, 1019-22.
• Hermanowski T., Jaworski R., Czech M., Pachocki R., 2001. Ocena kosztów związanych z występowaniem nadciśnienia tętniczego w Polsce. Nadciśnienie Tętnicze 5, 83-91.
• Holemans K., Aerts L., Van Assche F. A., 2003. Lifetime consequences of abnormal fetal pancreatic development. J. Physiol. 547, 11-20.
• Jacobson M. F., Brownell K. D., 2000. Small taxes on soft drinks and snack foods to promote health. Am. J. Publ. Health 90, 854-857.
• Kinalska I., Niewada M., Głogowski C., Krzyżanowska A., Gierczyński J., Łatek M., Kamiński B., 2004. Koszty cukrzycy typy 2 w Polsce (Badania CODIP). Diabetologia Praktyczna 5, 1-8.
• King H., Aubert R. E., Herman W. H., 1998. Globar Burden of Diabetes, 1995-2025. Diabet. Care 21, 1414-1431.
• Lim S., Lee H. K., Park K. S., Cho S. I., 2005. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determined by Korean National Health and Nutrition Examination Surveys. Diabet. Care 28, 1810-1812.
• Magnusson A. L., Waterman I. J., Wennergren M., Jansson T., Powell T. L., 2004. Triglyceride Hydrolase Activities and Expression of Fatty Acid Binding Proteins in the Human Placenta in Pregnancies Complicated by Intrauterine Growth Restriction and Diabetes. J. Clin. Endocrinol. Metabol. 89, 4607-4614.
• Malandro M. S., Beveridge M. J., Kilberg M. S., Novak D. A., 1996. Effect of low-protein diet-induced intrauterine growth retardation on rat placental amino acid transport. Am. J. Physiol. 271, 295-303.
• Mente A., Yusuf S., Islam S., Mcqueen M. J., Tanomsup S., Onen C. L., Rangarajan S., Gerstein H. C., Anand S. S., 2010. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J. Am. Coll. Cardiol. 55, 2390-2398.
• Neumann CH. H., Carroll B. A., 1984. Fetal Biometry and Intrauterine Growth Retardation. West. J. Med. 140, 414-420.
• Park J. H., Stoffers D. A., Nicholls R. D., Simmons R. A., 2008. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J. Clin. Invest. 118, 2316-2324.
• Rappange D. R., Brouwer W. B., Hoogenveen R. T., Van Baal P. H., 2009. Healthcare costs and obesity prevention: drug costs and other sector-specific consequences. Pharmacoeconomics 27, 1031-1044.
• Salonen M. K., Kajantie E., Osmond C., Forsén T., Ylihärsilä H., Paile-Hyvärinen M., Barker D. J. P., Eriksson J. G., 2009. Role of childhood growth on the risk of metabolic syndrome in obese men and women. Diabet. Metabol. 35, 94-100.
• Samaras T. T., Erick H., Storms L. H., 2003. Birthweight, Rapid Growth, Cancer, and Longevity: A Review. J. Nat. Med. Assoc. 95, 1170-1183.
• Soto N., Bazaes R. A., Pena V., Salazar T., Avila A., Iniguez G., Ong K. K., Dunger D. B., Mericq M. V., 2003. Insulin Sensitivity and Secretion Are Related to Catch-Up Growth in Small-for-Gestational-Age Infants at Age 1 Year: Results from a Prospective Cohort. J. Clin. Endocrinol. Metabol. 88, 3645-3650.
• Thiebaugeorges O., Fresson J., Audibert F., Guihard-Costa A. M., Frydman R., Droulle P., 2000. Diagnosis of small-for-gestational-age fetuses between 24 and 32 weeks, based on standard sonographic measurements. Ultrasound Obstet. Gynecol. 16, 49.
• Uncf (United Nations Children's Fund), 2001. Progress since the World Summit for Children: A statistical review.
• Unicef, 2000. The state of the world's children.
• Węgrzyn P., Kaźmierczak W., Fiegler P., Kamiński K., 2004. Wewnątrzmaciczne opóźnione wzrastanie płodu - analiza sposobu rozwiązania ciąży, przebiegu porodu oraz pourodzeniowego stanu noworodka. Ginekologia Praktyczna 12, 32-37.
• Who (World Health Organization), 2001. We the Children: End-decade review of the follow-up to the World Summit for Children. Report of the Secretary-General, WHO.